A novel inflammation‐related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate

Takuji Tanaka, Hiroyuki Kohno, Rikako Suzuki, +3

Cancer Science

Bystander killing effect of <scp>DS</scp>‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity

Yusuke Ogitani, Katsunobu Hagihara, Masataka Oitate, +2

Cancer Science

Reduced expression of <i>Dicer</i> associated with poor prognosis in lung cancer patients

Yoko Karube, Hisaaki Tanaka, Hirotaka Osada, +8

Cancer Science

YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity <i>in vitro</i> and <i>in vivo</i>

Shu Tian, Haitian Quan, Chengying Xie, +5

Cancer Science

Lipoxygenase‐mediated generation of lipid peroxides enhances ferroptosis induced by erastin and RSL3

Ryosuke Shintoku, Yuta Takigawa, Keiichi Yamada, +5

Cancer Science

Lipid PeroxidationCell DeathRedox BiologyFerroptosisOxidative Stress +14

From Brand Loyalty to E-Loyalty: A Conceptual Framework

Marcel Gommans, Krish S. Krishnan, Katrin B. Scheffold

Cancer Science

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor

Chengying Xie, Xiaozhe Wan, Haitian Quan, +4

Cancer Science

Novel combination of serum microRNA for detecting breast cancer in the early stage

Akihiko Shimomura, Sho Shiino, Junpei Kawauchi, +11

Cancer Science

Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study

Kuniko Sunami, Hitoshi Ichikawa, Takashi Kubo, +37

Cancer Science

Actionable Gene AberrationsCancer PathologyHospital‐based StudyGenetic EpidemiologyPathology +20

The ALK‐5 inhibitor A‐83‐01 inhibits Smad signaling and epithelial‐to‐mesenchymal transition by transforming growth factor‐β

Masayoshi Tojo, Yoshio Hamashima, Aki Hanyu, +5

Cancer Science